Aptose Shareholders Face 28% Premium Lock-In as Hanmi Deal Heads for Final Vote

The immediate event is now in final form. Aptose Biosciences has announced that Institutional Shareholder Services (ISS) has recommended shareholders vote FOR the acquisition by Hanmi. The deal is a cash offer of C$2.41 per share, representing a 28% premium to Aptose's 30-day VWAP of C$1.88 on the TSX. This is the final, binding proposal.

The mechanics are set. The reconvened special meeting to vote on the deal is today, March 31, 2026. The proxy deadline for shareholders to vote has already passed. The stock is trading at C$2.39, just below the offer price. This narrow gap indicates the market is pricing in a high probability of deal approval. The setup is clear: shareholders must vote, and the board is unanimously recommending they say yes.

The Mechanics: Why This Deal Now?

The deal is moving forward for clear strategic and financial reasons. The primary driver is the need for capital to fund a critical drug program. Aptose's board has unanimously recommended the deal, citing the liquidity and financial position of the company that the acquisition provides. This is directly tied to a new loan agreement signed just last month. The company has extended a US$11.1 million second amended and restated facility agreement with Hanmi, which will fund the advancement of its lead drug, Tuspetinib. This financial lifeline is the immediate catalyst for closing the deal now.

The procedural step of continuing from the Canada Business Corporations Act to Alberta's Business Corporations Act is a standard, non-controversial move. ISS noted that shareholder rights under the two statutes are largely similar and there would be no adverse impact. This technical change is a necessary formality to facilitate the arrangement under Alberta law, not a substantive shift.

The market's reaction confirms the deal's attractiveness. ISS's recommendation to vote FOR the deal is based on three key points: the offer price represents a premium to the unaffected price, the initial market reaction was positive, and there are no superior competing bids. The stock's price of C$2.39, just below the C$2.41 offer, shows the market is pricing in a high probability of approval. The board's unanimous backing and ISS's endorsement remove significant uncertainty, making the deal a near-certain outcome.

The bottom line is a straightforward trade. Aptose shareholders are being offered a 28% premium for their stock, providing immediate liquidity and certainty. In return, they are giving up future upside on a clinical program that requires continued external funding. The deal's mechanics are simple, but the timing is strategic: it locks in value before the next major clinical data readouts for Tuspetinib, which could create volatility. For shareholders, the choice is clear.

The Setup: Immediate Risk/Reward and Next Steps

The tactical setup is now binary. With the special meeting underway today, the primary catalyst is the vote outcome. The board is unanimously recommending approval, and ISS has backed that call. This removes the major uncertainty, making a yes vote the near-certain path forward. The key near-term risk is deal failure, which would likely cause a sharp re-rating of the stock back toward pre-announcement levels. The market is already pricing in a high probability of approval, with the stock trading just below the offer price.

Closing remains subject to customary conditions, including Court and TSX approvals. These are expected to be granted, but they represent the final procedural hurdles. The timeline is tight: the deal is expected to close shortly after those approvals are secured. For shareholders, the decision is made. Those who voted have locked in the C$2.41 cash offer. The stock's narrow gap to the offer price reflects the market's view that the deal is a done deal.

The bottom line is a straightforward, event-driven trade. The 28% premium provides immediate liquidity and certainty, which is the core value proposition. The risk is that the deal fails, but the evidence of board and ISS support makes that scenario unlikely. The next step is simply waiting for the vote to be counted and the approvals to come through.